Pharmacokinetics of Lisdexamfetamine (Vyvanse®) in Post-bariatric Surgery Patients

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE4

Total Enrollment

20 participants

Study Classification

INTERVENTIONAL

Study Start Date

2017-05-12

Study Completion Date

2019-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study is being conducted to evaluate how the body absorbs and processes the medication lisdexamfetamine (Vyvanse®). Subjects who are 9-15 months post gastric bypass surgery will be invited to participate. Non-surgical controls will also be enrolled based on a matching criteria to post gastric bypass subjects. Participants will be asked to complete one 12-hour study day and complete one 24-hour post dosing blood draw.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Bariatric Surgery and Pharmacokinetics of Dexamphetamine

NCT03460353

Obesity, Morbid

COMPLETED

Study to Examine the Effect of Gastric Bypass Surgery on Venlafaxine ER Blood Levels

NCT01867255

Bariatric Surgery Gastric Bypass Roux-en-Y Gastric Bypass

COMPLETED PHASE1

Bioavailability Study of SPD489 Administered With Two Different Means of Administration in Healthy Adult Volunteers

NCT01890785

Healthy Volunteers

COMPLETED PHASE1

A Study to Evaluate the Pharmacokinetics of VI-0521 in Subjects With Hepatic Impairment

NCT00768209

Hepatic Impairment

COMPLETED PHASE1

Pharmacokinetics and Safety of Single Subcutaneous Pasireotide (SOM230) in Subjects With Varying Degrees of Hepatic Function

NCT00698464

Hepatic Cirrhosis Alcoholism

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Lisdexamfetamine

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

OTHER

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

RYGB

Single dose of lisdexamfetamine 50 mg in RYGB patients

Group Type EXPERIMENTAL

Lisdexamfetamine

Intervention Type DRUG

lisdexamfetamine 50 mg single dose

Nonsurgical Controls

Single dose of lisdexamfetamine 50 mg in non-surgical controls

Group Type EXPERIMENTAL

Lisdexamfetamine

Intervention Type DRUG

lisdexamfetamine 50 mg single dose

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Lisdexamfetamine

lisdexamfetamine 50 mg single dose

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Male or female subjects.
2. Between the ages of 18 and 60 years at the time of informed consent. \*The upper age limit of 60 has been chosen as this medication carries some cardiovascular risk along with the fact that pharmacokinetics in elderly patients vary and may affect the homogeneity of the study.
3. Must be in good health as determined by physical exam, EKG, and medical history.

4a. Underwent RYGB 9-15 months prior (n=10 study completers) -or-

4b. Have not received bariatric surgery and are matched to the RYGB participants by BMI, age and sex (n= 10 study completers)

5\. Women of child bearing potential must be practicing a medically acceptable method of birth control and have a negative pregnancy test at baseline.

6\. No contraindications to receiving lisdexamfetamine in a single dose of 50 mg.

Exclusion Criteria

1. Allergy to lisdexamfetamine or any of its constituents.
2. Candidates who are pregnant or nursing.
3. Candidates currently receiving a medication that interacts with lisdexamfetamine, including concurrent use of a stimulant.
4. Subjects who smoke or used any nicotine products in the last six months.
5. Subjects who have a positive urine drug screen for drugs of abuse.
6. Candidates that for any reason cannot comply with the requirements of the study procedures.
7. Candidates experiencing clinically significant or unstable neurological, hepatic, renal or cardiovascular disease on laboratory or baseline EKG screening or any medical disorder that would put the participant at increased risk in the judgement of the investigator or physician.
8. Candidates currently or with a past history of meeting diagnostic criteria for schizophrenia, schizoaffective disorder, bipolar disorder, or other psychotic illness.
9. Candidates with any history of drug abuse or dependence.
10. Candidates with any history of alcohol dependence, or current usage that puts the candidate at risk in the judgement of the investigator or study physician.
11. Candidates who have participated in an investigational drug study in the past 30 days.
12. Significant iron deficient anemia that may impact the pharmacokinetics of lisdexamfetamine.
13. Participant with a significantly and persistently elevated resting blood pressure (\>140/90 mmHg) or pulse (\>100 bpm) after repeated measurement.

Minimum Eligible Age

18 Years

Maximum Eligible Age

60 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes